Relmada Therapeutics Inc RLMD:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 4:00 PM EDT
3.69quote price arrow up+0.05 (+1.37%)
Volume
63,531
52 week range
2.36 - 7.22
Loading...
  • Open3.62
  • Day High3.83
  • Day Low3.62
  • Prev Close3.64
  • 52 Week High7.22
  • 52 Week High Date03/04/24
  • 52 Week Low2.36
  • 52 Week Low Date06/28/23

Key Stats

  • Market Cap111.343M
  • Shares Out30.17M
  • 10 Day Average Volume0.13M
  • Dividend-
  • Dividend Yield-
  • Beta0.25
  • YTD % Change-10.87

KEY STATS

  • Open3.62
  • Day High3.83
  • Day Low3.62
  • Prev Close3.64
  • 52 Week High7.22
  • 52 Week High Date03/04/24
  • 52 Week Low2.36
  • 52 Week Low Date06/28/23
  • Market Cap111.343M
  • Shares Out30.17M
  • 10 Day Average Volume0.13M
  • Dividend-
  • Dividend Yield-
  • Beta0.25
  • YTD % Change-10.87

RATIOS/PROFITABILITY

  • EPS (TTM)-3.28
  • P/E (TTM)-1.12
  • Fwd P/E (NTM)-1.17
  • EBITDA (TTM)-103.702M
  • ROE (TTM)-87.51%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/09/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Relmada Therapeutics Inc

 

Profile

MORE
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of...
Charles Casamento
Independent Chairman of the Board
Sergio Traversa
Chief Executive Officer, Director
Maged Shenouda
Chief Financial Officer
Charles Ence
Chief Accounting, Compliance Officer
Address
2222 Ponce De Leon Blvd. 3Rd Floor
Coral Gables, FL
33134
United States

Top Peers

SYMBOLLASTCHG%CHG
HRBR
Harbor Diversified Inc
1.81-0.02-1.07%
OMER
Omeros Corp
3.40+0.25+7.94%
SCPH
scPharmaceuticals Inc
4.54+0.07+1.57%
VYNE
Vyne Therapeutics Inc
2.53+0.01+0.40%
CYTH
Cyclo Therapeutics Inc
1.45-0.01-0.68%